Browse drugs

…as 85.4% for galcanezumab, 81.3% for fremanezumab and 84.2% for erenumab; at 4 years it was 69.2%, 73.5% and 63.9% respectively. Among 6…

…vention less, but still 14/34 (41.2%), patients reported having oxycodone tablets left.Conclusion and Relevance The multifaceted interven…

…tervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. …

…erapeutic Guidelines. Antibiotics studied: aztreonam/avibactam, cefiderocol, ceftaroline, ceftazidime/avibactam, ceftobiprole, ceftolozane/…

… MAE = 1.15 ± 1.80 mg/L, MRE = 11.5 ± 8.6%.Population model for piperacillin-tazobactam: R2 = 0.86, MAE = 9.31 ± 19.33 mg/L, MRE = 38.4 ± 19.5%; after …

…stical significance the data suggest a favourable trend towards Dato-DXd, which could reflect its potential in terms of progression-free…

…brutinib (40.7%), acalabrutinib (30.5%), zanubrutinib (3.4%) or venetoclax (25.4%). 91.5% of them had at least one comorbidity and the med…

…ed apoptosis.The I+V regimen consists of three 28-day cycles of ibrutinib monotherapy, followed by the addition of venetoclax from cycle …

…l budget savings and broader prophylaxis coverage compared with palivizumab. Its single-dose schedule demonstrates greater economic efficie…

…Background and Importance PCSK9 inhibitors (alirocumab and evolocumab) effectively reduce Low-density lipoprotein (LDLc) and cardiova…

…ent, and outcomes of hypothyroidism in PC patients treated with apalutamide.Material and Methods This retrospective observational study inc…

…12 (10–60) 4.5 (0–80) 7.5 (0–10) 0 (0–10) 8.5 (3–10) 3.5 (0–10) Baricitinib 22 (21–40) 1 (0–18) 16 (5–40) 1 (0–10) 6 (0–1) 0 (0–1) 8 (0–5) …